Physician profile
Paul M Ehrlich
NPI 1770540403
$6,469.01
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,245 · 2020: $660 · 2021: $735 · 2022: $1,338 · 2023: $1,056 · 2024: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,677.39 | 2019-2023 | Nucala, Benlysta |
| Regeneron Healthcare Solutions, INC. | $923.58 | 2019-2023 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $813.35 | 2019-2024 | Breztri |
| Genzyme Corporation | $780.62 | 2019-2023 | |
| Csl Behring | $413.13 | 2019-2023 | Haegarda |
| Kaleo, INC. | $384.31 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $323.43 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $278.43 | 2019-2023 | |
| Incyte Corporation | $176.49 | 2022-2024 | Opzelura |
| Alk-Abello, INC | $140.08 | 2019 | |
| Pfizer INC. | $81.26 | 2020-2021 | |
| Octapharma USA, INC. | $78.76 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.60 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $51.56 | 2022 | |
| Shire North American Group INC | $49.45 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $46.80 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $45.17 | 2022 | |
| Grifols USA, LLC | $28.64 | 2022 | |
| Aimmune Therapeutics, INC. | $23.08 | 2022 | |
| Horizon Therapeutics Plc | $22.12 | 2023 | Actimmune |
| Eyevance Pharmaceuticals LLC | $21.93 | 2020 | |
| Phadia US INC. | $20.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.63 | 2020 | |
| Optinose US, INC. | $16.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Ehrlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.